Fate Therapeutics (FATE) Equity Ratio (2016 - 2025)
Fate Therapeutics (FATE) has disclosed Equity Ratio for 14 consecutive years, with 0.65 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio fell 10.18% year-over-year to 0.65, compared with a TTM value of 0.65 through Dec 2025, down 10.18%, and an annual FY2025 reading of 0.65, down 10.18% over the prior year.
- Equity Ratio was 0.65 for Q4 2025 at Fate Therapeutics, down from 0.68 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.76 in Q1 2023 and bottomed at 0.65 in Q4 2025.
- Average Equity Ratio over 5 years is 0.72, with a median of 0.73 recorded in 2021.
- The sharpest move saw Equity Ratio rose 19.28% in 2021, then fell 10.18% in 2025.
- Year by year, Equity Ratio stood at 0.74 in 2021, then fell by 6.9% to 0.69 in 2022, then increased by 6.11% to 0.73 in 2023, then decreased by 0.62% to 0.72 in 2024, then dropped by 10.18% to 0.65 in 2025.
- Business Quant data shows Equity Ratio for FATE at 0.65 in Q4 2025, 0.68 in Q3 2025, and 0.7 in Q2 2025.